Pharmaceutical compositions for treating cancer

1. A pharmaceutical composition comprising an anti-cancer drug and an inhibitor of bone morphogenetic protein 4 (BMP4) gene expression and/or an inhibitor of bone morphogenetic protein 4 (BMP4), wherein the anti-cancer drug excludes oxaliplatin and derivatives thereof, wherein the inhibitor of BMP4 gene expression is an interfering ribonucleic acid, wherein the interfering ribonucleic acid is a shRNA comprising the sequence selected from the group consisting of 5′-TGAGGTGACTCACCTCCATCAGACTCGGA-3′ (SEQ ID NO: 23) and 5′-GCCACTCGCTCTATGTGGACTTCAGCGAT-3′ (SEQ ID NO: 24), or functional variants thereof.

2. The pharmaceutical composition of claim 1 , wherein the anti-cancer drug is an anti-cancer drug comprising platinum-complexes.

3. The pharmaceutical composition of claim 2 , wherein the anti-cancer drug is cis-diamminedichloroplatinum (II) (CDDP, cis-platin), or carboplatin or a derivative thereof.

4. The pharmaceutical composition of claim 1 , wherein the anti-cancer drug is a drug used for the treatment of cancer selected from the group consisting of lung cancer, testicular cancer, breast cancer, colon cancer, ovarian cancer, head and neck cancer, esophageal cancer and gastric cancer.

5. The pharmaceutical composition of claim 4 , wherein the anti-cancer drug is an anti-gastric cancer drug selected from the group consisting of cisplatin.

6. A method of treating a patient suffering from cancer by administering a pharmaceutical composition of claim 1 .

7. The method of claim 6 , wherein the cancer is selected from the group consisting of lung cancer, testicular cancer, breast cancer, colon cancer, ovarian cancer, head and neck cancer, esophageal cancer and gastric cancer.

8. The method of claim 7 , wherein the cancer is gastric cancer.